ФАРМАКОЛОГИЯ ВЗАИМОДЕЙСТВИЯ РЕГУЛЯТОРНЫХ ПЕПТИДНЫХ СИСТЕМ ГОЛОВНОГО МОЗГА В МЕХАНИЗМАХ ПОДКРЕПЛЕНИЯ

Koob G.F. A role for corticotropin-releasing factor and urocortin in behavioral responses to stressors. /Koob G.F., Heinrichs S.C. // Brain Res. 1999. Vol.848. P.141-152.

Koob G.F. Addiction and the brain antireward system. /Koob G.F., Le Moal M. //Ann Rev Psychol 2008b;59:29–53.

Koob G.F. Alcoholism: allostasis and beyond. /Koob G.F. // Alcohol Clin. Exp. Res. 2003. V. 27. P.232–243.

Koob G.F. Corticotropin-releasing factor, norepinephrine and stress. /Koob G.F. // Biol Psychiatry 1999; 46:1167–1180.

Koob G.F. Drug abuse: Hedonic homeostatic dysregulation. /Koob G.F., Le Moal M. //Science 1997; 278:52–58.

Koob G.F. Drugs of abuse: anatomy, pharmacology, and function of reward pathways. /Koob G.F. // TrendsPharmacol Sci 1992; 13:177–184.

Koob G.F. Neuroadaptive mechanisms of addiction: studies on the extended amygdala. /Koob G.F. // Eur. Neuropsychopharmacol. 2003. V.13. P.442–452.

Koob G.F. Neuroscience of addiction. / Koob G.F., Sanna P.P., Bloom F.E // Neuron. 1998; 21:467–76. []

Koob G.F. Stress, corticotropin-releasing factor, and drug addiction. /Koob G.F. // Ann. N.Y. Acad. Sci. 1999. V. 897. P.27–45.

Koob G.F. The role of the striatopallidal and extended amygdala systems in drug addiction. /Koob G.F. // Ann. N.Y. Acad. Sci. 1999. V.877. P.445–460.

Kornetsky C. Euphorigenic drugs: Effects on the reward pathways of the brain. /Kornetsky C., Esposito R.U. // Fed Proc 1979;38:2473–2476.

Kornetsky C. The role of the olfactory tubercle in the effects of cocaine, morphine, and brain-stimulation reward. /Kornetsky C., Huston-Lyons D., Porrino L.J // Brain Res. 1991. V.541. P.75–81.

Korotkova T.M. Selective excitation of GABAergic neurons in the substantianigra of the rat by orexin/hypocretin in vitro. / Korotkova T.M., Eriksson K.S, Haas H.L., Brown R.E // RegulPept. 2002;104:83–89. []

Kostich W.A. Molecular identification and analysis of a novel human corticotropin-releasing factor (CRF) receptor: the CRF2gamma receptor. /Kostich W.A., Chen A., Sperle K., Largent B.L. // Mol. Endocrinol. 1998. V. 12. P.1077–1085.

Kretschmer B.D. Functional aspects of the ventral pallidum. /Kretschmer B.D. // Amino Acids. 2000. V.19. P.201–210.

Lall, S. Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. /Lall, S., Tung, L.Y.C., Ohlsson, C., Jansson, J.O., Dickson, S.L. // Biochemicaland Biophysical Research Communications 280 (1) – 2001 – Р.132–138.

Landgren, S. Association of Pro-Ghrelin and GHSR1A gene polymorphisms and haplotypes with heavy alcohol use and body mass. /Landgren, S., Jerlhag, E., Zetterberg, H., Gonzalez-Quintela, A., Campos, J., Olofsson, U., Nilsson, S., Blennow, K., Engel, J.A. // Alcoholism – Clinical and Experimental Research 32 (12) – 2008 – Р.2054–2061.

Landgren, S. Genetic variation of the ghrelin signaling system in females with severe alcohol dependence. /Landgren, S., Jerlhag, E., Hallman, J., Oreland, L., Lissner, L., Strandhagen, E., Thelle, D.S., Zetterberg, H., Blennow, K., Engel, J.A. // Alcoholism –Clinical and Experimental Research 34 (9) - 2010 – Р.1519–1524.

Larsson, A. Neurochemical and behavioral studies on ethanol and nicotine interactions. /Larsson, A., Engel, J.A. // Neuroscience and Biobehavioral Reviews 27 (8) – 2004 – Р.713–720.

Larsson, A. Voluntary ethanol intake increases extracellular acetylcholine levels in the ventral tegmental area in the rat. /Larsson, A., Edstrom, L., Svensson, L., Soderpalm, B., Engel, J.A. // Alcohol and Alcoholism 40 (5) - 2005 – Р.349–358.

Laviolette S.R. GABAA receptors in the ventral tegmental area control bidirectional reward signalling between dopaminergic and non-dopamingeric neural motivational systems. /Laviolette S.R., van der Kooy D. // Eur. J. Neurosci. 2001. V.13. P.1009–1015.

Le Doux J.E. Different projections of the central amygdaloid nucleus mediate autonomic and behavioral correlates of conditioned fear. /Le Doux J.E., Iwata J., Cicchetti P., Reis D.J. // J. Neurosci 1988; 8:2517–2529.

Lelas S. Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in rats. /Lelas S., Wong H., Li Y.W. et al. // J. Pharmacol. Exp. Ther. 2004. V. 309. P.293–302.

Lewis K. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. /Lewis K., Li C., Perrin M.H. et al. // Proc. Natl. Acad. Sci. USA. 2001. V. 98. P.7570–7575.

Li Y.W. Receptor occupancy of nonpeptide corticotropinreleasing factor 1 antagonist DMP696: correlation with drug exposure and anxiolytic efficacy. /Li Y.W., Hill G., Wong H. et al. // J. Pharmacol. Exp. Ther. 2003. V. 305. P.86–96.